Rapid-Infusion Rituximab in a Pediatric Population

Area of Science:

• Pediatric Hematology/Oncology
• Clinical Pharmacology

Background:

• Rituximab is an effective therapy for various pediatric conditions.
• Rapid infusion protocols aim to improve patient convenience and resource utilization.
• Previous studies suggest rituximab is generally safe in pediatric populations.

Purpose of the Study:

• To evaluate the safety and tolerability of a 90-minute rituximab infusion protocol in pediatric patients.
• To assess adverse drug reactions associated with rapid rituximab administration.
• To characterize the patient population receiving rapid rituximab infusions.

Main Methods:

• Retrospective review of 88 rituximab infusions in 22 pediatric patients.
• Primary endpoint: incidence and severity of adverse drug reactions.
• Secondary endpoints: patient demographics, indications, doses, infusion times, and comparison to standard rates.

Main Results:

• No dose-limiting adverse reactions were observed across 88 infusions.
• Three patients experienced mild (Grade 1) infusion-related adverse events.
• Two patients tolerated subsequent rapid infusions; one discontinued therapy.

Conclusions:

• A 90-minute rituximab infusion protocol is well-tolerated in pediatric patients with non-rheumatic diseases.
• The rapid infusion strategy appears safe and feasible for clinical use.
• Minimal infusion-related adverse events were noted, supporting its continued use.